The antitumor antibiotic mitomycin C is shown to form a covalent complex with calf thymus DNA under anaerobic conditions in the presence of either NADPH cytochrome c reductase/NADPH, xanthine oxidase/NADH, or the chemical reducing system H2/PtO2. Digestion of the complex with DNase I/snake venom diesterase/alkaline phosphatase yields a single mitomycin deoxyguanosine adduct as the major DNA alkylation product, identified as N2-(2",3,7"-diaminomitosen-l"a-yl) 2'-deoxyguanosine (Structure 2). Two minor adducts, 2-5% each of the total adduct pool, are isolated and identified as the 1"j8 stereoisomer of 2 (Structure 3), and 10"-decarbamoyl-2 (Structure 7). The same results were obtained with M13 DNA and poly(dG-dC) poly(dG-dC); however, in the latter case, a minor adduct apparently possessing two deoxyguanosine and one mitomycin unit is isolated. Digestion of the covalent mitomycin-calf thymus DNA complex with nuclease P1 yields four dinucleotide adducts, all of which consist of 2 linked at its 3' end to each of the four possible 5' nucleotides (A, T, G, and C). Upon treatment of each dinucleotide adduct with snake venom diesterase/alkaline phosphatase, 2 is released along with the corresponding free nucleoside. In apparent conflict with the present results, previous reports from another laboratory have indicated that modification of calf thymus DNA by mitomycin C under conditions identical to those described here result in the isolation of three mitomycin C mononucleotide adducts possessing linkages of the drug to N2 and 06 of guanine and N6 of adenine. Evidence is shown suggesting that the latter adducts are actually three of the above four dinucleotide derivatives of 2 obtained independently by us and, thus, all of them in fact possess an identical N2-mitosenylguanine adduct moiety. Model-building studies indicate an excellent fit of the guanine N2-linked drug molecule inside the minor groove of B-DNA with no appreciable distortion of the DNA structure.
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Mitomycin C (MC; Structure 1), a potent antibiotic and clinically used antitumor agent, is known to interact covalently with DNA in vivo and in vitro. This is manifested by the reversible melting behavior of MC-exposed DNA, attributed to formation of covalent crosslinks between the complementary strands (1) and by covalent association of the ultraviolet chromophore of MC to DNA (2) . These processes require reduction of MC into a transiently activated form, which is thought to occur in cells and can be mimicked easily in vitro chemically or enzymatically (1) . The cytotoxicity of MC is most likely a direct result of DNA alkylation, as indicated by the parallels in biological activity of MC with a number of known "DNA damaging agents": selective inhibition of DNA replication (1) , strong induction of the SOS response (3) was isolated in our laboratory. Its structure was rigorously established as N2-(2",8,7"-diaminomitosen-l"a-yl),2'-deoxyguanosine (the term "mitosene" refers to the bracketed structure in 2 without substituents at the 1", 2", and 7" Abbreviations: MC, mitomycin C; M, 2,f,7-diaminomitosen-1-yl; SVD, snake venom diesterase; br, binding ratio (mol of MC per mol of mononucleotide); poly(dG-dC), poly(dG-dC)-poly(dG-dC).
Proc. Natl. Acad. Sci. USA 83 (1986) 6703 positions) (Structure 2) (7, 8) . [In our first report (7) , the M moiety was stated to be linked to the 06 rather than N2 position of guanine. A reinvestigation of this structural assignment, however, revealed that the correct structure is 2 (8) .] With this reference adduct in hand, we turned to the isolation and characterization of adducts formed from treatment of DNA with MC under analogous activation conditions. We report here that reductively activated MC binds with extraordinary specificity to the N2 position of guanine residues in DNA, yielding upon enzymatic digestion the previously elucidated monofunctional adduct 2; furthermore, 2 accounts singularly for 90% or more of the total adduct population.
These findings are in disagreement with reports from Shudo's laboratory, published while this study was in progress, stating that three MC DNA adducts are formed in roughly equal amounts under comparable conditions; i.e., bearing the M moiety linked to the N2 and O6 positions of guanine, and the N6 position of adenine (9) . Our thorough reinvestigation of the published experimental procedures (9) indicates that the three substances were apparently different dinucleotide derivatives of the same deoxyguanosine adduct 2 possessing the common general structure d[pG (M) 
, and nuclease P1 were from Pharmacia P-L Biochemicals; DNase I and SVD (phosphodiesterase I) were from Cooper Biomedical (Malvern, PA). 10-Decarbamoyl-MC was synthesized as described (10) . Authentic samples of adduct 2 were prepared as described (8 were mixed in 0.015 M Tris HCl (pH 7.4) and hydrogenated by a published procedure (7) . Isolation and determination of the binding ratio (br; mol of MC per mol of mononucleotide) of the resulting MC-DNA complex was accomplished as described (2) . ( (Fig. la) . With the exception of the early-eluting unmodified nucleosides, only one major peak is evident in the pattern, at 45 min. The two minor peaks, at 39 and =120 min, each represent <5% of the peak area of the 45-min major peak. MC-calf thymus DNA complexes formed under enzymatic activation (NADPH cytochrome c reductase or xanthine oxidase) yielded patterns ( Fig. 1 b and c) essentially identical to those obtained using H2/PtO2 (Fig. la) . M13 DNA and denatured calf thymus DNA also gave similar patterns (not shown). MC-poly(dG-dC) complexes (H2/PtO2 or NADPH cytochrome c reductase) also yielded the same pattern of adducts (Fig. ld) , except for an additional minor adduct peak marked X.
Identification of the Major MC-DNA Adduct as 2. The major component of each of the adduct patterns described above (45-minute peak; Fig. 1 a-d) was isolated by either HPLC or Sephadex G-25 chromatography (7) . Direct comparisons of this material with authentic 2 (7, 8) were made with respect to the following criteria: (i) HPLC elution time: identical (Fig. le) ; single homogeneous peak when mixed with authentic 2. (ii) Sephadex G-25 elution volume (7): identical. (iii) UV spectra (Fig. 2) obtained at three pH values: identical. (iv) Conversion to adduct triacetate 8 shows a very good comparison between the 1H NMR spectra of 8 obtained in this work and an authentic sample (8) (Fig. 3) . Furthermore, the HPLC retention times, fast atom bombardment mass spectra, and Fourier transform IR spectra (not shown; see ref. Elucidation of Minor Adducts. The minor adduct eluting at 120 min ( Fig. 1 a-d) was identified as 3, the 1"-3 stereoisomer of2 by direct comparison of its HPLC retention time (Fig. le) and characteristic UV with authentic 3 (8) . The 39-min minor adduct ( Fig. 1 a-d) was identified as 7, the 10"-decarbamoyl derivative of 2 by the following: (i) When authentic pure 2 was incubated under the same conditions as those used to digest the MC-DNA complex, a minor peak appeared in the HPLC at 39 min, in addition to major unchanged 2 at 45 min (Fig. lf). (ii) This same 39-min peak was the single major adduct obtained when 10"-decarbamoyl-MC was substituted for MC in the complexation reaction with DNA or poly(dGdC) (data not shown). These results strongly suggest that 7 is formed from 2 via hydrolysis ofthe 10"-carbamoyl substituent during the enzymatic digestion of the MC-polynucleotide complex.
Nuclease P1 Digestion Products of the MC-DNA Complex. Fig. 4a . With a more polar eluant (6:94 CH3CN/0.3% aqueous NH4Cl) to distribute the products over a larger retention time, the apparent triplet at >11 min (Fig. 4a) resolved into a complex series of products with various peak intensities and widths; thus, it is clear that the "triplet" in Fig. 4a Fig. 4b. Peaks 1-4 exhibited elution times that were identical to members of the authentic synthetic dinucleoside phosphate adduct series 4 (i.e., dN = dA, dG, dC, and dT; Fig. 4b, Inset) . No MC adduct was eluted before peak 1. Nuclease P1/alkaline phosphatase digestion of a MCpoly(dG-dC) complex (br, 0.12) gave rise to a single detectable MC-linked dinucleoside phosphate 4 (dN = dG) (Fig.  4d) , which was identical to peak 1 in Fig. 4b .
Adducts from Nuclease P1 Digestion Are Further Degradable to 2 by SVD/Alkaline Phosphatase. An Further digestion ofthe purified 4 peak (dN = dC) with SVD/alkaline phosphatase; the early eluting peak is deoxycytidine and the late eluting peak is 2. above nuclease P1 digest was adjusted to 0.001 M MgCl2 and pH was adjusted to 8.5, and was incubated with alkaline phosphatase (0.5 unit/A260 unit) and SVD (2.5 units/A260 unit) for 2 hr at 37°C. Direct HPLC analysis (Fig. 4c) indicated essentially a single adduct, 2, as judged by its spectral and chromatographic properties. Application of the same digestion conditions to any of the four isolated nuclease P1/alkaline phosphatase products ( Fig. 4b; peaks 1-4 ) results in the quantitative release of 2 and the corresponding nucleoside in a 1:1 ratio; for example, treatment of pure peak 1 (4; dN = dC) (Fig. 4d) gave rise to the early eluting deoxycytidine peak and a later eluting peak, 2 (Inset).
Summary: The Adducts from Nuclease Pl/Alkaline Phosphatase Digestion Are MC-Dinucleoside Phosphates, 4. This is concluded from their identity with the authentic synthetic substances with respect to the following properties: (i) HPLC retention times; (ii) degradation by alkaline phosphatase/SVD to 2 and deoxynucleoside (molar ratio, 1:1) (e.g., see Not to SVD. Both 4 (dN = dC) and 6 (dN = dC) were incubated with nuclease P1, followed by alkaline phosphatase, and analyzed directly by HPLC. Although 4 remained unchanged even in the presence of a 100-fold increase of nuclease P1 concentration, 6 was degraded readily to 2 and deoxycytidine. On the other hand, SVD/alkaline phosphatase degraded both 4 (dN = dC) and 6 (dN = dC) to 2 and deoxycytidine. Characterization of the Minor Adduct X (Fig. ld) . The UV spectrum of X was very similar to that of 2 ( Fig. 2) except that the A252/A310 ratio was higher in the former (2.8 vs. 2.3, respectively). Base analysis (not shown) indicates guanine as the only base in X.
DISCUSSION
These results demonstrate unambiguously that the major covalent adduct formed between MC and DNA in vitro in a variety of systems is the guanine N2-linked mitosene 2. The other two minor adducts also bear a guanine N2 linkage (3, 7); 7 is a secondary degradation product of 2, whereas 3 is the 1"-,B stereoisomer of 2, arising from attack ofthe guanine NH2 group from the 3 rather than the a side of activated MC. Model-building studies (not shown) indicate severe steric hindrance to this mode of binding to native B-DNA structure. Therefore, 3 may actually be formed preferentially in transiently denatured segments of DNA. Accordingly, twice as much 3 was obtained from denatured as from native DNA. The reaction between reductively activated MC and deoxyguanosine itself yields 2 and 3 in almost equal amounts (8) .
Our finding that the N2 position of guanine is the only detectable site of binding of reductively activated MC in DNA is in conflict with a previous report by Shudo and coworkers (9) . Reinvestigation of the reported work revealed a likely source of error as follows: according to the authors (9), nuclease P1 digestion of MC-modified calf thymus DNA Biochemistry: Tomasz et al.
gave a three-peak pattern on HPLC, the components of which were used directly for structural studies and were concluded to be mononucleotides substituted by MC at N2 and O6 of guanine and N6 of adenine, respectively. In our hands, this nuclease P1 digest gave a similar HPLC pattern (Fig. 4a) (2, 13) ; the favorable secondary interactions of covalently anchored M units with the surrounding minor groove readily account for this fact. The location of the 2" NH3' group inside the groove-i.e., the site of minimum electrostatic potential-is especially favorable (14) . The stabilizing effect of bound MC on DNA duplex structure is analogous to that of anthramycin, a molecule of similar size and binding site (15) . (iv) The experimental saturation binding ratio of MC to poly(dG-dC) is 0.25 (i.e., one MC every 2 base pairs) (16) . According to the proposed model, at a (CG),, sequence the guanine of every second base pair may be substituted by MC; this way, the drug molecules fill the minor groove completely, with headto-tail H bonds to one another (Fig. 5b) , in agreement with the experimental saturation br.
Results with synthetic polyribonucleotide analogs are also consistent with guanine-N2 as binding site: binding was uninhibited to poly(06-methylguanine) or poly(G, 7-methylguanine) but inhibited to poly(I) (17) .
On the Origin of the MC-Induced Crosslinks in DNA. The monofunctional adducts reported here, 2, 3, and 7, account essentially quantitatively for the observed amount of MC bound to DNA. What is then the origin of the interstrand crosslinks of MC, which are detectable by several physical methods (1) but the molecular structure ofwhich has not been demonstrated to date? Presumably, the resolution of this conflict lies in the very low incidence of crosslinking of DNA by MC: typically, <1 crosslink per 106-Da DNA (1); thus, a "crosslink"-type adduct could escape detection by UV methods. In the MC-poly(dG-dC) digests, however, a promising crosslink candidate, X, is clearly discernible (=5% of monofunctional adducts) [based on the UV and base analysis data (see Results)]. A peak corresponding to X also becomes evident in native DNA-MC complexes, which have higher br values (data not shown).
Activation of MC in Vitro vs. in Vivo. MC-reducing activity, which catalyzes the formation of MC metabolites as well as covalent binding and crosslinking of MC to DNA, has been demonstrated in bacterial and mammalian cell extracts (1) . NADPH cytochrome c reductase was specifically implicated in intracellular activation of MC (18) . Microsomal preparations (19) as well as purified flavoenzymes (xanthine oxidase, NADPH cytochrome c reductase; ref. 20) or H2/PtO2 (19) catalyze the formation of an identical series of MC metabolites and, as shown here, identical DNA modifications in vitro. It is most likely, therefore, that the DNA-modifying effects of MC in vivo are similar or identical to those described here. The elucidation of the nature of the adducts and their analytical properties now opens the way to MC adduct analysis in vivo. Such analyses will be essential to the search for correlations between the biological effects of MC and its covalent modifications of DNA. Furthermore, these methods of adduct analysis should be adaptable to MC analogs, currently of considerable interest in cancer chemotherapy.
